Study Warns of Significant Increases in Diabetes and Cardiovascular Disease by 2060 Mohebi R, Chen C, Ibrahim N, et al. Cardiovascular Disease Projections in the United States Based on the…
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS Southlake,…
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) — HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an…
SOUTHLAKE, Texas, June 15, 2022 — Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG…
